Show simple item record

dc.contributor.authorGeorge, A
dc.contributor.authorKaye, S
dc.contributor.authorBanerjee, S
dc.date.accessioned2017-05-26T15:22:24Z
dc.date.issued2017-05
dc.identifier.citationNature reviews. Clinical oncology, 2017, 14 (5), pp. 284 - 296
dc.identifier.issn1759-4774
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/659
dc.identifier.eissn1759-4782
dc.identifier.doi10.1038/nrclinonc.2016.191
dc.description.abstractThe treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. Germ line BRCA mutation status is now established as a predictive biomarker of potential benefit from treatment with a PARP inhibitor; therefore, knowledge of the BRCA status of an individual patient with ovarian cancer is essential, in order to guide treatment decisions. BRCA testing was previously offered only to women with a family or personal history of breast and/or ovarian cancer; however, almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA testing. A strategy to enable more widespread implementation of BRCA testing in routine care is, therefore, necessary. In this Review, we summarize data from key clinical trials of PARP inhibitors and discuss how to integrate these agents into the current treatment landscape of ovarian cancer. The validity of germ line BRCA testing and other promising biomarkers of homologous-recombination deficiency will also be discussed.
dc.formatPrint-Electronic
dc.format.extent284 - 296
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectOvarian Neoplasms
dc.subjectGerm-Line Mutation
dc.subjectGenes, BRCA1
dc.subjectGenes, BRCA2
dc.subjectModels, Genetic
dc.subjectFemale
dc.subjectClinical Trials as Topic
dc.subjectGenetic Testing
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.titleDelivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/nrclinonc.2016.191
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature reviews. Clinical oncology
pubs.issue5
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume14
pubs.embargo.terms12 months
icr.researchteamMedicine Drug Development Unit (Kaye)en_US
dc.contributor.icrauthorBanerjee, Susanaen
dc.contributor.icrauthorMarsden,en
dc.contributor.icrauthorKaye, Stanley Bernarden


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record